Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes

NCT01970033 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Placebo
DRUG: SP2086 50 mg b.i.d.
DRUG: SP2086 100 mg q.d.

Sponsor

Jiangsu HengRui Medicine Co., Ltd.